RNA Therapy Clinical Trials Market (By Modality: RNA Interference, Antisense Therapy, Messenger RNA, Oligonucleotide, Non-antisense, Non-RNAi; By Clinical Trials Phase: Phase I, Phase II, Phase III, Phase IV; By Therapeutic Areas: Rare Diseases, Anti-infective, Anticancer, Neurological, Alimentary/Metabolic, Musculoskeletal, Cardiovascular Respiratory, Sensory, Others) - Global Industry Analysis, Size, Share, Growth, Trends, Regional Outlook, and Forecast 2024-2033
Chapter 1. Introduction
1.1. Research Objective
1.2. Scope of the Study
1.3. Definition
Chapter 2. Research Methodology (Premium Insights)
2.1. Research Approach
2.2. Data Sources
2.3. Assumptions & Limitations
Chapter 3. Executive Summary
3.1. Market Snapshot
Chapter 4. Market Variables and Scope
4.1. Introduction
4.2. Market Classification and Scope
4.3. Industry Value Chain Analysis
4.3.1. Raw Material Procurement Analysis
4.3.2. Sales and Distribution Channel Analysis
4.3.3. Downstream Buyer Analysis
Chapter 5. COVID 19 Impact on RNA Therapy Clinical Trials Market
5.1. COVID-19 Landscape: RNA Therapy Clinical Trials Industry Impact
5.2. COVID 19 - Impact Assessment for the Industry
5.3. COVID 19 Impact: Global Major Government Policy
5.4. Market Trends and Opportunities in the COVID-19 Landscape
Chapter 6. Market Dynamics Analysis and Trends
6.1. Market Dynamics
6.1.1. Market Drivers
6.1.2. Market Restraints
6.1.3. Market Opportunities
6.2. Porter’s Five Forces Analysis
6.2.1. Bargaining power of suppliers
6.2.2. Bargaining power of buyers
6.2.3. Threat of substitute
6.2.4. Threat of new entrants
6.2.5. Degree of competition
Chapter 7. Competitive Landscape
7.1.1. Company Market Share/Positioning Analysis
7.1.2. Key Strategies Adopted by Players
7.1.3. Vendor Landscape
7.1.3.1. List of Suppliers
7.1.3.2. List of Buyers
Chapter 8. Global RNA Therapy Clinical Trials Market, By Modality
8.1. RNA Therapy Clinical Trials Market, by Modality, 2024-2033
8.1.1 RNA Interference
8.1.1.1. Market Revenue and Forecast (2021-2033)
8.1.2. Antisense Therapy
8.1.2.1. Market Revenue and Forecast (2021-2033)
8.1.3. Messenger RNA
8.1.3.1. Market Revenue and Forecast (2021-2033)
8.1.4. Oligonucleotide, Non-antisense, Non-RNAi
8.1.4.1. Market Revenue and Forecast (2021-2033)
Chapter 9. Global RNA Therapy Clinical Trials Market, By Clinical Trials Phase
9.1. RNA Therapy Clinical Trials Market, by Clinical Trials Phase, 2024-2033
9.1.1. Phase I
9.1.1.1. Market Revenue and Forecast (2021-2033)
9.1.2. Phase II
9.1.2.1. Market Revenue and Forecast (2021-2033)
9.1.3. Phase III
9.1.3.1. Market Revenue and Forecast (2021-2033)
9.1.4. Phase IV
9.1.4.1. Market Revenue and Forecast (2021-2033)
Chapter 10. Global RNA Therapy Clinical Trials Market, By Therapeutic Areas
10.1. RNA Therapy Clinical Trials Market, by Therapeutic Areas, 2024-2033
10.1.1. Rare Diseases
10.1.1.1. Market Revenue and Forecast (2021-2033)
10.1.2. Anti-infective
10.1.2.1. Market Revenue and Forecast (2021-2033)
10.1.3. Anticancer
10.1.3.1. Market Revenue and Forecast (2021-2033)
10.1.4. Neurological
10.1.4.1. Market Revenue and Forecast (2021-2033)
10.1.5. Alimentary/Metabolic
10.1.5.1. Market Revenue and Forecast (2021-2033)
10.1.6. Musculoskeletal
10.1.6.1. Market Revenue and Forecast (2021-2033)
10.1.7. Cardiovascular Respiratory
10.1.7.1. Market Revenue and Forecast (2021-2033)
10.1.8. Sensory
10.1.8.1. Market Revenue and Forecast (2021-2033)
10.1.9. Others
10.1.9.1. Market Revenue and Forecast (2021-2033)
Chapter 11. Global RNA Therapy Clinical Trials Market, Regional Estimates and Trend Forecast
11.1. North America
11.1.1. Market Revenue and Forecast, by Modality (2021-2033)
11.1.2. Market Revenue and Forecast, by Clinical Trials Phase (2021-2033)
11.1.3. Market Revenue and Forecast, by Therapeutic Areas (2021-2033)
11.1.4. U.S.
11.1.4.1. Market Revenue and Forecast, by Modality (2021-2033)
11.1.4.2. Market Revenue and Forecast, by Clinical Trials Phase (2021-2033)
11.1.4.3. Market Revenue and Forecast, by Therapeutic Areas (2021-2033)
11.1.5. Rest of North America
11.1.5.1. Market Revenue and Forecast, by Modality (2021-2033)
11.1.5.2. Market Revenue and Forecast, by Clinical Trials Phase (2021-2033)
11.1.5.3. Market Revenue and Forecast, by Therapeutic Areas (2021-2033)
11.2. Europe
11.2.1. Market Revenue and Forecast, by Modality (2021-2033)
11.2.2. Market Revenue and Forecast, by Clinical Trials Phase (2021-2033)
11.2.3. Market Revenue and Forecast, by Therapeutic Areas (2021-2033)
11.2.4. UK
11.2.4.1. Market Revenue and Forecast, by Modality (2021-2033)
11.2.4.2. Market Revenue and Forecast, by Clinical Trials Phase (2021-2033)
11.2.4.3. Market Revenue and Forecast, by Therapeutic Areas (2021-2033)
11.2.5. Germany
11.2.5.1. Market Revenue and Forecast, by Modality (2021-2033)
11.2.5.2. Market Revenue and Forecast, by Clinical Trials Phase (2021-2033)
11.2.5.3. Market Revenue and Forecast, by Therapeutic Areas (2021-2033)
11.2.6. France
11.2.6.1. Market Revenue and Forecast, by Modality (2021-2033)
11.2.6.2. Market Revenue and Forecast, by Clinical Trials Phase (2021-2033)
11.2.6.3. Market Revenue and Forecast, by Therapeutic Areas (2021-2033)
11.2.7. Rest of Europe
11.2.7.1. Market Revenue and Forecast, by Modality (2021-2033)
11.2.7.2. Market Revenue and Forecast, by Clinical Trials Phase (2021-2033)
11.2.7.3. Market Revenue and Forecast, by Therapeutic Areas (2021-2033)
11.3. APAC
11.3.1. Market Revenue and Forecast, by Modality (2021-2033)
11.3.2. Market Revenue and Forecast, by Clinical Trials Phase (2021-2033)
11.3.3. Market Revenue and Forecast, by Therapeutic Areas (2021-2033)
11.3.4. India
11.3.4.1. Market Revenue and Forecast, by Modality (2021-2033)
11.3.4.2. Market Revenue and Forecast, by Clinical Trials Phase (2021-2033)
11.3.4.3. Market Revenue and Forecast, by Therapeutic Areas (2021-2033)
11.3.5. China
11.3.5.1. Market Revenue and Forecast, by Modality (2021-2033)
11.3.5.2. Market Revenue and Forecast, by Clinical Trials Phase (2021-2033)
11.3.5.3. Market Revenue and Forecast, by Therapeutic Areas (2021-2033)
11.3.6. Japan
11.3.6.1. Market Revenue and Forecast, by Modality (2021-2033)
11.3.6.2. Market Revenue and Forecast, by Clinical Trials Phase (2021-2033)
11.3.6.3. Market Revenue and Forecast, by Therapeutic Areas (2021-2033)
11.3.7. Rest of APAC
11.3.7.1. Market Revenue and Forecast, by Modality (2021-2033)
11.3.7.2. Market Revenue and Forecast, by Clinical Trials Phase (2021-2033)
11.3.7.3. Market Revenue and Forecast, by Therapeutic Areas (2021-2033)
11.4. MEA
11.4.1. Market Revenue and Forecast, by Modality (2021-2033)
11.4.2. Market Revenue and Forecast, by Clinical Trials Phase (2021-2033)
11.4.3. Market Revenue and Forecast, by Therapeutic Areas (2021-2033)
11.4.4. GCC
11.4.4.1. Market Revenue and Forecast, by Modality (2021-2033)
11.4.4.2. Market Revenue and Forecast, by Clinical Trials Phase (2021-2033)
11.4.4.3. Market Revenue and Forecast, by Therapeutic Areas (2021-2033)
11.4.5. North Africa
11.4.5.1. Market Revenue and Forecast, by Modality (2021-2033)
11.4.5.2. Market Revenue and Forecast, by Clinical Trials Phase (2021-2033)
11.4.5.3. Market Revenue and Forecast, by Therapeutic Areas (2021-2033)
11.4.6. South Africa
11.4.6.1. Market Revenue and Forecast, by Modality (2021-2033)
11.4.6.2. Market Revenue and Forecast, by Clinical Trials Phase (2021-2033)
11.4.6.3. Market Revenue and Forecast, by Therapeutic Areas (2021-2033)
11.4.7. Rest of MEA
11.4.7.1. Market Revenue and Forecast, by Modality (2021-2033)
11.4.7.2. Market Revenue and Forecast, by Clinical Trials Phase (2021-2033)
11.4.7.3. Market Revenue and Forecast, by Therapeutic Areas (2021-2033)
11.5. Latin America
11.5.1. Market Revenue and Forecast, by Modality (2021-2033)
11.5.2. Market Revenue and Forecast, by Clinical Trials Phase (2021-2033)
11.5.3. Market Revenue and Forecast, by Therapeutic Areas (2021-2033)
11.5.4. Brazil
11.5.4.1. Market Revenue and Forecast, by Modality (2021-2033)
11.5.4.2. Market Revenue and Forecast, by Clinical Trials Phase (2021-2033)
11.5.4.3. Market Revenue and Forecast, by Therapeutic Areas (2021-2033)
11.5.5. Rest of LATAM
11.5.5.1. Market Revenue and Forecast, by Modality (2021-2033)
11.5.5.2. Market Revenue and Forecast, by Clinical Trials Phase (2021-2033)
11.5.5.3. Market Revenue and Forecast, by Therapeutic Areas (2021-2033)
Chapter 12. Company Profiles
12.1. IQVIA
12.1.1. Company Overview
12.1.2. Product Offerings
12.1.3. Financial Performance
12.1.4. Recent Initiatives
12.2. ICON Plc.
12.2.1. Company Overview
12.2.2. Product Offerings
12.2.3. Financial Performance
12.2.4. Recent Initiatives
12.3. Laboratory Corporation of America Holdings
12.3.1. Company Overview
12.3.2. Product Offerings
12.3.3. Financial Performance
12.3.4. Recent Initiatives
12.4. Charles River Laboratories International, Inc.
12.4.1. Company Overview
12.4.2. Product Offerings
12.4.3. Financial Performance
12.4.4. Recent Initiatives
12.5. PAREXEL International Corp.
12.5.1. Company Overview
12.5.2. Product Offerings
12.5.3. Financial Performance
12.5.4. Recent Initiatives
12.6. Syneos Health
12.6.1. Company Overview
12.6.2. Product Offerings
12.6.3. Financial Performance
12.6.4. Recent Initiatives
12.7. Medpace Holdings, Inc.
12.7.1. Company Overview
12.7.2. Product Offerings
12.7.3. Financial Performance
12.7.4. Recent Initiatives
12.8. PPD Inc.
12.8.1. Company Overview
12.8.2. Product Offerings
12.8.3. Financial Performance
12.8.4. Recent Initiatives
12.9. Novotech
12.9.1. Company Overview
12.9.2. Product Offerings
12.9.3. Financial Performance
12.9.4. Recent Initiatives
12.10. Veristat, LLC.
12.10.1. Company Overview
12.10.2. Product Offerings
12.10.3. Financial Performance
12.10.4. Recent Initiatives
Chapter 13. Research Methodology
13.1. Primary Research
13.2. Secondary Research
13.3. Assumptions
Chapter 14. Appendix
14.1. About Us
14.2. Glossary of Terms
No cookie-cutter, only authentic analysis – take the 1st step to become a Precedence Research client
Report Description
Get a Sample